In invasive breast cancer (BC), the Ki67 labelling index is an essential tool used to classify luminal (oestrogen receptor [ER]‐positive) tumours into two IHC surrogate subclasses: luminal A and B, which have different outcomes and therapeutic approaches.3, 4. This evidence concerns the gene MKI67 and breast cancer.